Phase 3 Survey Results Demonstrate Patient and Healthcare Professional Satisfaction with Olanzapine LAI March 31, 2025 March 31, 2025
FDA Acceptance of Supplemental New Drug Application for UZEDY® as a Treatment for Patients with Bipolar I Disorder February 25, 2025 February 25, 2025
Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia February 10, 2025 February 10, 2025
The EIB Reaffirms Confidence in Medincell by Permanently Waiving Two Financial Covenants in its Loan Agreement February 6, 2025
